Those markers include von Hippel-Lindau tumor suppressor (pVHL), placental S100 (S100P), mammary serine protease inhibitor (maspin), insulin-like growth factor II messenger RNA binding protein-3 (IMP3), mesothelin, prostate stem cell antigen (PSCA), annexin A8, fascin, claudin 4, claudin 18, p53, SMAD family member 4 (DPC4/SMAD4), carcinoembryonic antigen (CEA), cytokeratin (CK) 17, CK19, mucin (MUC) 1, MUC2, MUC5AC, cancer antigen 19-9 (CA19-9), and EPCAM.
2, CK7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, caudal type homeobox 2 [CDX2], pVHL, S100P, IMP3, maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA, EPCAM, CEA, and CA19-9) in 60 cases of pancreatic DADC on tissue microarray and routine tissue sections.
2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/ SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas by using 60 cases of pancreatic DAC on routine and tissue microarray (TMA) sections.
2, CK7, CK20, CK17, CK19); (2) mucin gene products (MUC1, MUC2, MUC4, MUC5AC, MUC6); (3) tumor suppressor genes and transcription factors (p53, DPC4/SMAD4, CDX2, pVHL); and (4) tumor-associated proteins (S100P, IMP-3, maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA, MOC31, CEA, CA19-9).
2, CK7, CK19, MUC1, MUC6, CA19-9, MOC31, PSCA, mesothelin, an nexin A8, claudin 4, and claudin 18; (4) normal pancreatic ducts were usually negative for IMP-3, maspin, S100P, CK17, MUC2, MUC4, and MUC5AC; (5) 60% of adenocar cinoma cases showed loss of expression of DPC4/SMAD4; and (6) strong background staining was frequently seen with fascin (including staining for endothelial cells and stromal cells), PSCA, and annexin A8.
Benign ducts were frequently positive for CA19-9, mesothelin, MUC1, MUC6, MOC31, PSCA, claudin 4, and claudin 18, which limits the application of these markers in distinguishing DAC from nonneoplastic pancreatic ducts.
Normal pancreatic ducts and acini are usually positive for MOC31, PSCA, claudin 4, and claudin 18, which limits the application of these markers in the distinction between pancreatic DAC and reactive ducts.